Mark Emberton holds the post of Professor in Interventional Oncology at University College London and is Associate Professor at Middlesex University, London. At UCLH he is Pathway Director for Urological Cancer for UCL Partners. He is also Honorary Clinical Director of the Clinical Effectiveness Unit at the Royal College of Surgeons of England. His clinical and research interests are focused mainly on diseases of the prostate gland, both benign and malignant. In prostate cancer much of his activity is at present focused on evaluating minimally invasive therapies for localised prostate cancer. This work encompasses the fields of precise characterisation of disease as well as targeting therapies. A current interest includes the non invasive evaluation of men at risk of having prostate cancer.

Professor Emberton is also interested in the methodological aspects of clinical research, particularly on the use of alternatives to the randomised control trial in surgery. He is involved in guideline production and appraisal and is interested in the formulation of evidence based management policies. He is an active researcher, lectures widely and has published over 100 peer reviewed publications as well as numerous books and chapters. He is a founding Partner of London Urology Associates, and is a Trustee of Prostate Action.